Surface modification of esophageal stent materials by a drug-eluting layer for better anti-restenosis function

Yuxin Bai, Kun Zhang, Ru Xu, Hongtao Liu, Fangxia Guan, Huiwen Luo, Ye Chen, Jingan Li

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It is generally accepted that stent implantation is the mainstream therapy in clinics for esophageal cancer in the later period. However, the restenosis caused by tumor cells, epithelial cells, and fibroblasts seriously interferes with the stent medical application and limits its long-term services. To address this conundrum, a series of drug-eluting stents were invented and verified to be feasible in the early stage after implantation, but the limited drug loading and good cell compatibility of the stent materials may lead to more serious restenosis and further endanger the patient's life. In previous work, we modified the esophageal stent material 317L stainless steel (317L SS) surface with a poly-dopamine/poly-ethylenimine layer (PDA/PEI), which had strong anti-tumor functions. In this contribution, we employed a usual drug in clinic, 5-fluorouracil (5-Fu), with series of density onto the PDA/PEI modified 317L SS to investigate the influence of 5-Fu immobilization on the anti-restenosis function. The surface characterization including 5-Fu quantity, atomic force microscopy (AFM). Water contact angle measurement indicated successful preparation of the PDA/PEI/5-Fu layers. The spectrophotometric characterization revealed that the immobilized 5-Fu rapidly released over 24 h. However, the Eca109, Het-1A, and L929 cells culture results suggested that the released 5-Fu made a significant contribution to improving the apoptosis and necrosis of these pathological cells, and the PDA/PEI/5-Fu layers maintain the consistent anti-restenosis function on their surfaces with the PDA/PEI layer after 24 h. All the results demonstrated the PDA/PEI/5-Fu layers' excellent ability to suppress esophageal tumor cells, epithelial cells, and fibroblasts, suggesting a potential application on the surface modification of esophageal stents for better anti-restenosis function.

Original languageEnglish (US)
Article number215
JournalCoatings
Volume8
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Stents
Fluorouracil
Surface treatment
drugs
dopamine
Pharmaceutical Preparations
Tumors
Fibroblasts
Stainless Steel
Stainless steel
Cells
tumors
fibroblasts
Medical applications
Cell death
Angle measurement
stainless steels
implantation
Cell culture
Contact angle

Keywords

  • 5-fluorouracil
  • Anti-restenosis
  • Esophageal stent materials
  • Functional layer
  • Poly-dopamine
  • Poly-ethylenimine

ASJC Scopus subject areas

  • Surfaces, Coatings and Films
  • Materials Chemistry
  • Surfaces and Interfaces

Cite this

Surface modification of esophageal stent materials by a drug-eluting layer for better anti-restenosis function. / Bai, Yuxin; Zhang, Kun; Xu, Ru; Liu, Hongtao; Guan, Fangxia; Luo, Huiwen; Chen, Ye; Li, Jingan.

In: Coatings, Vol. 8, No. 6, 215, 01.06.2018.

Research output: Contribution to journalArticle

Bai, Yuxin ; Zhang, Kun ; Xu, Ru ; Liu, Hongtao ; Guan, Fangxia ; Luo, Huiwen ; Chen, Ye ; Li, Jingan. / Surface modification of esophageal stent materials by a drug-eluting layer for better anti-restenosis function. In: Coatings. 2018 ; Vol. 8, No. 6.
@article{0e8234ab4d1146e7a6741eab1f551064,
title = "Surface modification of esophageal stent materials by a drug-eluting layer for better anti-restenosis function",
abstract = "It is generally accepted that stent implantation is the mainstream therapy in clinics for esophageal cancer in the later period. However, the restenosis caused by tumor cells, epithelial cells, and fibroblasts seriously interferes with the stent medical application and limits its long-term services. To address this conundrum, a series of drug-eluting stents were invented and verified to be feasible in the early stage after implantation, but the limited drug loading and good cell compatibility of the stent materials may lead to more serious restenosis and further endanger the patient's life. In previous work, we modified the esophageal stent material 317L stainless steel (317L SS) surface with a poly-dopamine/poly-ethylenimine layer (PDA/PEI), which had strong anti-tumor functions. In this contribution, we employed a usual drug in clinic, 5-fluorouracil (5-Fu), with series of density onto the PDA/PEI modified 317L SS to investigate the influence of 5-Fu immobilization on the anti-restenosis function. The surface characterization including 5-Fu quantity, atomic force microscopy (AFM). Water contact angle measurement indicated successful preparation of the PDA/PEI/5-Fu layers. The spectrophotometric characterization revealed that the immobilized 5-Fu rapidly released over 24 h. However, the Eca109, Het-1A, and L929 cells culture results suggested that the released 5-Fu made a significant contribution to improving the apoptosis and necrosis of these pathological cells, and the PDA/PEI/5-Fu layers maintain the consistent anti-restenosis function on their surfaces with the PDA/PEI layer after 24 h. All the results demonstrated the PDA/PEI/5-Fu layers' excellent ability to suppress esophageal tumor cells, epithelial cells, and fibroblasts, suggesting a potential application on the surface modification of esophageal stents for better anti-restenosis function.",
keywords = "5-fluorouracil, Anti-restenosis, Esophageal stent materials, Functional layer, Poly-dopamine, Poly-ethylenimine",
author = "Yuxin Bai and Kun Zhang and Ru Xu and Hongtao Liu and Fangxia Guan and Huiwen Luo and Ye Chen and Jingan Li",
year = "2018",
month = "6",
day = "1",
doi = "10.3390/coatings8060215",
language = "English (US)",
volume = "8",
journal = "Coatings",
issn = "2079-6412",
publisher = "MDPI AG",
number = "6",

}

TY - JOUR

T1 - Surface modification of esophageal stent materials by a drug-eluting layer for better anti-restenosis function

AU - Bai, Yuxin

AU - Zhang, Kun

AU - Xu, Ru

AU - Liu, Hongtao

AU - Guan, Fangxia

AU - Luo, Huiwen

AU - Chen, Ye

AU - Li, Jingan

PY - 2018/6/1

Y1 - 2018/6/1

N2 - It is generally accepted that stent implantation is the mainstream therapy in clinics for esophageal cancer in the later period. However, the restenosis caused by tumor cells, epithelial cells, and fibroblasts seriously interferes with the stent medical application and limits its long-term services. To address this conundrum, a series of drug-eluting stents were invented and verified to be feasible in the early stage after implantation, but the limited drug loading and good cell compatibility of the stent materials may lead to more serious restenosis and further endanger the patient's life. In previous work, we modified the esophageal stent material 317L stainless steel (317L SS) surface with a poly-dopamine/poly-ethylenimine layer (PDA/PEI), which had strong anti-tumor functions. In this contribution, we employed a usual drug in clinic, 5-fluorouracil (5-Fu), with series of density onto the PDA/PEI modified 317L SS to investigate the influence of 5-Fu immobilization on the anti-restenosis function. The surface characterization including 5-Fu quantity, atomic force microscopy (AFM). Water contact angle measurement indicated successful preparation of the PDA/PEI/5-Fu layers. The spectrophotometric characterization revealed that the immobilized 5-Fu rapidly released over 24 h. However, the Eca109, Het-1A, and L929 cells culture results suggested that the released 5-Fu made a significant contribution to improving the apoptosis and necrosis of these pathological cells, and the PDA/PEI/5-Fu layers maintain the consistent anti-restenosis function on their surfaces with the PDA/PEI layer after 24 h. All the results demonstrated the PDA/PEI/5-Fu layers' excellent ability to suppress esophageal tumor cells, epithelial cells, and fibroblasts, suggesting a potential application on the surface modification of esophageal stents for better anti-restenosis function.

AB - It is generally accepted that stent implantation is the mainstream therapy in clinics for esophageal cancer in the later period. However, the restenosis caused by tumor cells, epithelial cells, and fibroblasts seriously interferes with the stent medical application and limits its long-term services. To address this conundrum, a series of drug-eluting stents were invented and verified to be feasible in the early stage after implantation, but the limited drug loading and good cell compatibility of the stent materials may lead to more serious restenosis and further endanger the patient's life. In previous work, we modified the esophageal stent material 317L stainless steel (317L SS) surface with a poly-dopamine/poly-ethylenimine layer (PDA/PEI), which had strong anti-tumor functions. In this contribution, we employed a usual drug in clinic, 5-fluorouracil (5-Fu), with series of density onto the PDA/PEI modified 317L SS to investigate the influence of 5-Fu immobilization on the anti-restenosis function. The surface characterization including 5-Fu quantity, atomic force microscopy (AFM). Water contact angle measurement indicated successful preparation of the PDA/PEI/5-Fu layers. The spectrophotometric characterization revealed that the immobilized 5-Fu rapidly released over 24 h. However, the Eca109, Het-1A, and L929 cells culture results suggested that the released 5-Fu made a significant contribution to improving the apoptosis and necrosis of these pathological cells, and the PDA/PEI/5-Fu layers maintain the consistent anti-restenosis function on their surfaces with the PDA/PEI layer after 24 h. All the results demonstrated the PDA/PEI/5-Fu layers' excellent ability to suppress esophageal tumor cells, epithelial cells, and fibroblasts, suggesting a potential application on the surface modification of esophageal stents for better anti-restenosis function.

KW - 5-fluorouracil

KW - Anti-restenosis

KW - Esophageal stent materials

KW - Functional layer

KW - Poly-dopamine

KW - Poly-ethylenimine

UR - http://www.scopus.com/inward/record.url?scp=85051583745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051583745&partnerID=8YFLogxK

U2 - 10.3390/coatings8060215

DO - 10.3390/coatings8060215

M3 - Article

AN - SCOPUS:85051583745

VL - 8

JO - Coatings

JF - Coatings

SN - 2079-6412

IS - 6

M1 - 215

ER -